Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma

IMPORTANCE: A phase 2 trial comparing talimogene laherparepvec plus ipilimumab vs ipilimumab monotherapy in patients with advanced unresectable melanoma found no differential benefit in progression-free survival (PFS) but noted objective response rates (ORRs) of 38.8% (38 of 98 patients) vs 18.0% (1...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Dermatol
Main Authors: Almutairi, Abdulaali R., Alkhatib, Nimer S., Oh, Mok, Curiel-Lewandrowski, Clara, Babiker, Hani M., Cranmer, Lee D., McBride, Ali, Abraham, Ivo
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439581/
https://ncbi.nlm.nih.gov/pubmed/30477000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2018.3958
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados